Introduction
Dlk1 (Pref-1, FA1) is a transmembrane and secreted protein. 1 It is a member of the epidermal growth factor-like family with homologies to Notch/Delta/Serrate, containing a signal peptide, followed by six epidermal growth factor-like repeats, a transmembrane domain, and a short intracellular tail. 1 Unlike other delta-family members, Dlk1 lacks the DSL motif, which may be crucial for the interaction with the Notch family of molecules, 1 suggesting that Dlk1 may exert its activity independent of the Notch receptors. Dlk1 is present in animals from birds to mammals and is an imprinted gene. 2 The protein is expressed in a variety of fetal and selected adult tissues and is thought to participate in embryonic growth, 1 hematopoiesis, 1 and wound healing. 3 It is downregulated during adipocyte differentiation; addition of recombinant soluble Dlk1 inhibits adipocyte differentiation of 3T3-L1 cells 1 and antisense Dlk1 increases adipocyte differentiation of Balb 3T3. 4 In the grandular epithelial cells of the developing pancreas, this protein decreases in an age-dependent manner. 1 Dlk1 is highly expressed in neuroblastoma and small-cell lung carcinoma and has been suggested to play an important role in tumorigenesis of these cells. 1 Neuroblastoma cell lines treated with agents that induced differentiation towards the chromaffin lineage increased their expression of Dlk1, while compounds that induced differentiation towards the neural phenotype decreased Dlk1 levels. 1 The role of Dlk1 in hematopoiesis has not been clearly defined. 5, 6 Stromal cells of the bone marrow can produce Dlk1, which may promote hematopoiesis. 5 Soluble Dlk1-IgG Fc chimeric protein inhibited the clonal growth of lineage-marker negative (Lin-) bone marrow cells stimulated by GM-CSF, G-CSF, or M-CSF in the presence of stem cell factor (SCF). 6 It may be involved in stromal cell-pre-B cell interactions. 5 Also, T cells in the developing thymus express Dlk1 on their cell surface; 6 and in fetal thymus organ cultures, thymocyte cellularity is increased by exogenous dimeric Dlk1 fusion proteins 6 and it is expressed at higher levels in the thymus during fetal development than in adult mice. 7 Microarray data by others and ourselves found that Dlk1 mRNA was markedly upregulated in CD34 þ hematopietic marrow stem cells from patients with low-risk MDS compared with normal individuals. 8, 9 The present studies show that Dlk1 is dysregulated in selected cases of MDS and AML, and Dlk1 contributes to normal hematopoiesis and B lymphocyte development.
Materials and methods

Cell culture and chemical reagents
Cell lines generously provided include NB4 (acute promyelocytic leukemia (AML-M3) cell line from Dr Lanotte (Hopital Saint-Louis, Paris, France)); KCL22 (chronic myelogenous leukemia cell line, Dr I Miyoshi (Kochi University, Kochi, Japan)); CMK (megakaryocytic leukemia, Dr T Sato (Chiba University, Chiba, Japan)); HEL, OCIM-I and HEL-R (erythroid leukemia, Dr T Papayannopoulou (University of Washington, Seattle, WA, USA)); and TF-1 (erythroid leukemia, Dr K Kitamura (Tokyo University, Tokyo, Japan)). KG-1 (early AML cell line) was established by our group. All other cells were obtained from the American Type Culture Collection (Rockville, MD, USA) and cultured as described. K562 cells were treated with either 40 mM hemin (Sigma, St Louis, MO, USA) for 48 h to induce erythroid differentiation as monitored by hemoglobin concentrations as described 10 or 50 nM 12-O-tetradecanoylphorbol-acetate (TPA) (Sigma, St Louis, MO, USA) for p5 days to induce megakaryocytic differentiation, monitored by expression levels of Integrin b3.
Brefeldin A and concanamycin A were purchased from Sigma (St Louis, MO, USA). K562 cells (1 Â 10 6 cells/ml) were cultured with either drug at the indicated concentrations for 4 h.
Patient and normal samples
Samples were from 60 newly diagnosed cases of MDS and 31 AML patients. Normal bone marrow CD34 þ cells were obtained from 11 healthy donors. CD34 þ cells from MDS and normal bone marrow were obtained from the mononuclear cell fraction (Ficoll density separation) followed by immunomagnetic bead selection with monoclonal murine antihuman CD34 antibodies using the Auto MACs automated separation system (Miltenyi Biotec, Mö nchengladbach, Germany). Yield and purity of the positively selected CD34 þ cells were evaluated by flow cytometry (FACScan) (Becton Dickinson, Heidelberg, Germany). Written informed consent was obtained in keeping with institutional policies.
AML mononuclear cells were separated using gradient centrifugation with Ficoll-Paque (Pharmacia, Uppsala, Sweden). At the time of diagnosis, the leukemic cells generally represented 60-99% of the mononuclear cell fraction.
Real-time RT-PCR assay
Total RNA was isolated from cell lines and clinical samples using Trizol reagent (Gibco, BRL) according to the standard protocol. Total RNA (1 mg) was processed directly to cDNA by reverse transcription with Superscript II (Life Technologies, Inc.) according to the manufacturer's protocol in a total volume of 20 ml and used for real-time RT-PCR, the details are provided in Supplementary Information.
Level of mRNA of each gene was evaluated as a ratio to the level of ribosomal 18S RNA to standardize the quantity of cDNAs of each sample. Furthermore, levels of Dlk1 mRNA from the various samples were quantified as relative values to those present in K562 cells; the relative value of Dlk1 transcripts in K562 cells as measured by real-time RT-PCR, was regarded as 100.
ELISA
Using prospectively collected serum samples from 121 normal individuals, 16 MDS, four myelofibrosis, 10 polycythemia rubra vera, and 10 essential thrombocythemia patients, serum Dlk1 was quantified using the sandwich ELISA technique based on polyclonal anti-FA1 (anti-Dlk1) antibodies purified by immunospecific affinity chromatography as previously described. 12 The normal values for serum Dlk1 are based on the concentrations in the serum samples from healthy donors.
Gene expression analysis by oligonucleotide microarrays
CD34
þ bone marrow cells from healthy individuals were cultured in vitro with TPO to induce megakaryocytic differentiation as previously described. 13 The cells were harvested on days 0, 4, 7, and 11 for expression profiling. Total RNA was extracted and used for RNA expression analysis using HG-U133A microarray (Affymetrix Inc.) and analyzed by the Microarray Analysis Suite 5.0 (Affymetrix, Inc.) and GeneSpring software version 4.2 (Silicon Genetics, San Carlos, CA, USA) as previously described. 8 The expression level of GAPDH, as determined by GeneChip assay, was required to be greater than 5000 (raw data) and was measured as 'present' (Affymetrix Call) in all of the samples. The experiments were performed in triplicates for each of the time points.
Cell transfection and Western blot
The expression vector pcDNA-Dlk1 was constructed by placing full-length human Dlk1 cDNA into the pcDNA3.1 vector (Invitrogen). The constructs were transfected into K562 cells by electroporation and transfectants were selected for their G418 resistance (800 mg/ml). Dlk1 cDNA sequence was subcloned into the pBI vector (Clontech Laboratories, Palo Alto, CA, USA) to generate pBI-Dlk1. Empty vector or pBI-Dlk1 were transfected with pTK-Hyg plasmids into Tet-Off K562 cells. Transfectants were selected for their resistance to G418 (800 mg/ ml) and hygromycin (200 mg/ml). The Dlk1-expressing clones were detected by Western blot analysis. Western blot analysis was performed as previously described.
14 Anti-Dlk1 polyclonal antibody (C-19) (Santa-Cruz, Santa-Cruz, CA, USA) and anti-GAPDH antibody (Reseach Diagnostic, Flanders, NJ, USA) were used.
Cell proliferation in liquid culture and clonogenic assays
Viable cells were counted using the trypan blue dye exclusion method beginning in 24-well plates at 1 Â 10 5 cells/well; and because FBS can contain Dlk1, 15 experiments were performed with both 10 and 1% FBS. Each experiment was performed in triplicate, and results represent the mean7s.d. of three experiments.
Dlk1 knockout (KO) mice 16 as well as age 6-8-weeks-old control mice were analyzed. Peripheral blood was obtained by heart puncture. Mononuclear cells from both bone marrow and spleens were separated by Ficoll Hypaque density centrifugation (Amersham Pharmacia, Uppsala, Sweden) and studied for their myeloid, erythroid, and megakaryocyte clonogenic growth as recommended by Stem Cell Technologies Inc. (Vancouver, CA, USA) and as previously reported. 5 Details of the cell culture experiments are provided in Supplementary information.
Flow cytometric analysis
Studies were performed as previously described using B220/ CD45R (RA3-6B2), CD43 (Ly-48), CD4 (L3T4), CD8a (Ly-2), CD19, murine IgM (R6-60.2), and CD34 (RAM34) (Pharmingen) monoclonal antibodies conjugated with either fluorescein isothiocyanate (FITC), phycoerythrin (PE), or peridinin chlorophyll protein (PerCP).
Results
MDS and AML cells overexpress Dlk1
Dlk1 mRNA expression in CD34 þ hematopoietic stem cells was examined in individuals with MDS using real-time RT-PCR. Level of Dlk1 mRNA in K562 cells was high and was used as an arbitrary standard (100%) for quantification of Dlk1 mRNA in other samples. Dlk1 mRNA was nearly undetectable in CD34 þ cells from 11 normal individuals, but levels were high in six of 
Serum levels of Dlk1 are high in some RA patients
Since Dlk1 is both a membrane and secreted protein, we measured levels of Dlk1 protein in the sera of patients with MDS, myeloproliferative disorders and normal individuals ( Figure 2 ). Whereas levels of Dlk1 protein in serum from almost all normal individuals were less than p50 ng/ml, high levels were detected in four of 10 patients with RA (40%) and two of 10 individuals with essential thrombocythemia (20%) (Figure 2 ).
Dlk1 is a secreted protein that causes cellular proliferation of K562 cells
Although K562 cells prominently expressed Dlk1 mRNA (Figure 1c ), low expression of Dlk1 protein was detected by Western blotting in these cells (data not shown). We hypothesized that most of the Dlk1 protein generated in these hematopoietic cells was secreted; and therefore, it was not detected in the cellular lysates by Western blot. This was confirmed by treatment of K562 cells with either brefeldin A or coneanamycin A, which inhibits protein transportation to the outside of the cells. Levels of Dlk1 protein in K562 cells markedly increased as shown by Western blot (data not shown).
To examine the effect of Dlk1 on cellular proliferation, we generated K562 cells stably expressing Dlk1. Three stable clones expressing Dlk1 and three control clones (Neo) were isolated (Figure 3a) . Each grew similarly in the presence of 10% FBS, but the Dlk1 expressing clones grew faster than controls in a low concentration of FBS (1%) (Figure 3a) . Further, to confirm the proliferative activity of Dlk1 in K562 cells, we generated a tetracycline-inducible clone, pBI Tet Dlk1-cl5. In the absence of doxycycline, expression of Dlk1 was induced; and withdrawal of this antibiotic from the culture media, shut off the expression of Dlk1 (Figure 3b ). Induced expression of Dlk1 in K562 cells again enhanced their proliferation in culture media containing 1% FBS (Figure 3b) . To elucidate the mechanisms of the proliferative activity of Dlk1, we analyzed the levels of cell cycle regulatory proteins in these cell lines. However, no difference was detected in levels of Rb, cyclin D1, and p21
WAF1
proteins between stable Dlk1 expressing clones of K562 and control clones (data not shown).
Hematopoiesis in Dlk1 KO mice
In order to understand further the function of Dlk1, hematopoiesis was studied in Dlk1 KO mice. Analysis of peripheral blood of Dlk1 KO mice showed that they had hematocrits (38% vs 44%, KO vs wild type (WT)), white blood cell counts (7.3 vs 8.4 Â 10 3 /ml, KO vs WT) and platelet counts (604 vs 805 Â 10 3 / ml, KO vs WT); however, P-values were not significantly different between Dlk1 KO and WT mice. Overall bone marrow cellularity, differential counts, percentage of red cell precursors (TER119 þ ), and common hematopoietic stem cells (CD34 þ ) were similar in the Dlk1 KO and WT mice (data on request).
The progenitor cells in the marrows of Dlk1 KO and WT mice were assessed by a variety of in vitro clonogenic assays using growth factors specific for the various cell lineages (see Materials and methods). Dlk1 KO mice had significantly more megakaryocyte colony-forming cell (CFU-MK) colonies (mean 53.877.7) than the WT mice (mean 43.273.3) (Po0.001) (Figure 4a ) significantly more granulocyte colony-forming cell (CFU-G) colonies (mean 32.5710.7) than WT mice (mean 17.575.0) when the marrows were grown with G-CSF alone (Po0.01) (Figure 4b) , and significantly fewer pre-B lymphocyte colonies (mean 8.675.1) than WT mice (mean 20.776.1) (Po0.01) (Figure 4c ). The number of bone marrow granulocytemacrophage precursors (CFU-GM and CFU-M), and erythroid precursors (BFU-E and CFU-E) were comparable between the Dlk1 KO and WT mice (data not shown). (Figure 4d) . In contrast, a mean 1471.4 pre-B lymphocyte colonies formed from bone marrows of Dlk1 KO mice; addition of mDlk1 (5 ng/ml) increased the number of pre-B lymphocyte colonies (2776.3) (Po0.01) (Figure 4e) .
Splenic weights of Dlk1 KO mice were less than those in WT mice at p8 weeks after birth (Figure 5a ). For example, mean weight of spleens at 6 weeks was 157738 (7s.d.) mg in WT mice, and 5274.2 mg in Dlk1 KO mice. This difference was also reflected in splenic sizes (Figure 5b) . Splenic sizes and weights were similar by 16 weeks of age (Figure 5a ). Since Dlk1 KO mice had fewer pre-B lymphocyte colonies compared with WT mice as measured by clonogenic assay of bone marrow cells, we analyzed B-cell development in the spleens. Although the difference in the size of spleens between Dlk1 WT and KO mice was dramatic at 6 weeks, no difference in their lymphoctye populations was detected between the Dlk1 WT and KO mice (data not shown). In contrast, whereas the population of B220 þ sIgM þ mature B cells in the spleens of Dlk1 WT mice was 51% at the 16th week, this population was only 33% at the 16th week in the Dlk1 KO mice (Figure 5c) . Also, the population of B220 þ CD43 À pre-B lymphocytes increased gradually (62% at 16 weeks) in WT mice, but this population reached only 45% at 16 weeks in Dlk1 KO mice (Figure 5d) . No difference was detected in T lymphocyte populations (CD3, CD4, CD8) between Dlk1 KO and WT mice at any age (data not shown).
Discussion
In this study, we have found high expression of Dlk1 mRNA in AML and MDS patients. Interestingly, samples from two patients with RA and RAEB-T (patients #1 and #2, respectively, in (10) ET (10) Normal (102) RA (10) RAEB (6) MF (4) Figure 2 Dlk1 serum levels in MDS, myeloproliferative disorders and normal individuals: Dlk1 levels were determined by ELISA. MF, myelofibrosis; PV, polycythemia vera; and ET, essential thrombocythemia. Numbers in parenthesis indicate the number of samples examined. 
Dlk1 in normal and abnormal hematopoiesis
S Sakajiri et al Figure 1b ) had very high levels of Dlk1 (490% of the level found in K562 cells) and very low levels of platelets (1.0 and 1.5 Â 10 4 /ml, respectively). Since we have only two cases with very high levels of Dlk1, we cannot conclude an association between platelet production and Dlk1 levels, but this possible association deserves further attention. Our data suggest that expression of Dlk1 is associated with CD34 þ MDS cells, early erythroid and megakaryoblastic AML cells as well as maturing normal megakaryocytes. Mechanism of overexpression of Dlk1 mRNA in MDS and AML is unclear and requires further study. Since Dlk1 is an imprinted gene and Dlk1 is transcribed from only the paternal allele in normal human, 2 loss of imprinting might occur in selected MDS and AML samples associated with overexpression of this gene.
Forced expression of Dlk1 in K562 cells enhanced their proliferation. High expression of Dlk1 in MDS and AML could provide them with a growth advantage over their normal hematopoietic counterparts. Mechanism by which Dlk1 enhances cellular proliferation is unclear at this time.
Dlk1 KO mice display growth retardation, obesity, blepharophimosis, skeletal malformation, and increased serum lipid metabolites. 16 Similar symptoms occur in humans with maternal uniparental disomy for chromosome 14 (mUDP14). 17 Lack of Dlk1 may be responsible for some of the symptoms observed in humans with mUPD14. Dlk1 is an imprinted gene residing on chromosome 14, and the gene is transcribed only from the paternal allele. Since patients with mUPD14 disease have disomy of the maternal allele of chromosome 14, Dlk1 will not be transcribed in these patients. 17 Hematopoietic abnormalities in individuals with mUDP14 have not been emphasized. Detailed analysis of hematopoiesis in the Dlk1 KO mice showed enhanced CFU-G and CFU-MK clonal growth, but decreased pre-B lymphocyte colony formation. Addition of the soluble form of Dlk1 to bone marrow cells from Dlk1 KO mice normalized the numbers of CFU-G and pre-B lymphocyte colony numbers. Despite impairment of clonogenic growth of several lineages, no significant difference in the peripheral blood cell counts were detected in the Dlk1 KO mice. A compensating mechanism might allow hematopoetic normality. Perhaps Dlk1 plays a more important role in embryonic hematopoiesis and becomes less important with development. By analogy, Notch1 conditional KO mice have a normal peripheral blood profile except for the T-cell compartment, but closer scrutiny shows hematopoietic abnormalities of these mice. 18 At 6-8 weeks of age, spleens of Dlk1 KO mice were smaller than those in WT mice. However, no abnormalities of lymphocyte contents were noted in their spleens. The cause of these small spleens might be nutritional, since Dlk1 KO mice have nutritional abnormalities and are small at birth. 16 Impairment of B-cell development was noted in spleens of Dlk1 KO mice at 16 weeks of age; and as mentioned above, their clonogenic growth of pre-B cells from the bone marrow of Dlk1 was impaired. Our data suggest that Dlk1, especially the soluble form of Dlk1, may play an important role in B lymphocyte development. These data buttress the experiments suggesting that Dlk1 is important for B-cell development in the presence of IL7 and stromal cells. High expression of Notch1 is frequently detected in AML; 19 and as mentioned, Notch1 conditional KO mice have impaired T-cell development. 20 Taken together, the data suggest that Notch1 and Dlk1 enhance cellular proliferation and play a role in lineage-specific development of lymphocytes. Recent data suggest that Notch1 is also critical for hematopoietic stem cell generation; 21 the role of Dlk1 in normal and abnormal hematopiesis requires additional studies.
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